1. Home
  2. STRO vs ABOS Comparison

STRO vs ABOS Comparison

Compare STRO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$8.89

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.29

Market Cap

147.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRO
ABOS
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.4M
147.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
STRO
ABOS
Price
$8.89
$2.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
6
Target Price
★ $47.23
$7.60
AVG Volume (30 Days)
279.9K
★ 574.6K
Earning Date
11-05-2026
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $38,419,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.72
$1.50
52 Week High
$43.85
$3.60

Technical Indicators

Market Signals
Indicator
STRO
ABOS
Relative Strength Index (RSI) 21.28 58.01
Support Level N/A $2.13
Resistance Level $16.99 $2.44
Average True Range (ATR) 1.24 0.16
MACD -0.18 0.06
Stochastic Oscillator 7.84 96.75

Price Performance

Historical Comparison
STRO
ABOS

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: